4-(6-phenylpyridazin-3-yl)morpholine | 107213-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(6-phenylpyridazin-3-yl)morpholine
• CAS: 107213-70-7
• 化学式: C₁₄H₁₅N₃O
• 分子量: 241.293
• InChiKey: VXNFJTPCSZEJRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  三丁基苯基锡 、 4-(6-氯哒嗪-3-基)吗啉 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 以41%的产率得到4-(6-phenylpyridazin-3-yl)morpholine
  参考文献：
  名称：

  An Electrochemical Nickel-Catalyzed Arylation of 3-Amino-6-Chloropyridazines

  摘要：

  3-Amino-6-aryl- and 3-amino-6-heteroarylpyridazines have been obtained in generally good yield using a nickel-catalyzed electrochemical cross-coupling between 3-amino-6-chloropyridazines and aryl or heteroaryl halides at room temperature. Comparative experiments involving classical palladium-catalyzed reactions, such as Suzuki, Stille, or Negishi cross-couplings, reveal that the electrochemical method can constitute a reliable alternative tool for biaryl formation. A possible reaction mechanism is proposed on the basis of electrochemical analyses.

  DOI：

  10.1021/jo3022428

文献信息

• Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents
  作者：Stéphane Sengmany、Mathilde Sitter、Eric Léonel、Erwan Le Gall、Gervaise Loirand、Thierry Martens、Didier Dubreuil、Florian Dilasser、Morgane Rousselle、Vincent Sauzeau、Jacques Lebreton、Muriel Pipelier、Rémy Le Guével

  DOI：10.1016/j.bmcl.2018.12.050

  日期：2019.3

  Various 3-amino-, 3-aryloxy- and alkoxy-6-arylpyridazines have been synthesized by an electrochemical reductive cross-coupling between 3-amino-, 3-aryloxy- or 3-alkoxy-6-chloropyridazines and aryl or heteroaryl halides. In vitro antiproliferative activity of these products was evaluated against a representative panel of cancer cell lines (HuH7, CaCo-2, MDA-MB-231, HCT116, PC3, NCI-H727, HaCaT) and

  通过3-氨基-，3-芳氧基-或3-烷氧基-6-氯哒嗪与芳基或杂芳基卤化物之间的电化学还原交叉偶联，已经合成了各种3-氨基-，3-芳氧基-和烷氧基-6-芳基哒嗪。评估了这些产品对代表性癌细胞系（HuH7，CaCo-2，MDA-MB-231，HCT116，PC3，NCI-H727，HaCaT）的体外抗增殖活性，并强调了更有效衍生物的致癌性预防在建立人类乳腺癌细胞系MDA-MB 468-Luc与p44 / 42和Akt依赖性信号传导途径的相互作用之前，已对MDA-MB 468-Luc进行了研究。
• Pyridazine Compounds, Compositions and Methods
  申请人：Watterson Martin

  公开号：US20080318899A1

  公开（公告）日：2008-12-25

  The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

  本发明涉及新型化合物和制备和使用它们的方法。具体而言，本发明提供吡嗪化合物和/或相关的杂环衍生物，包括这些化合物的组合物，以及使用吡嗪化合物和/或相关的杂环衍生物和组合物的方法，用于调节细胞通路（例如信号转导通路），用于治疗或预防炎症性疾病（例如阿尔茨海默病），用于研究、药物筛选和治疗应用。
• PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS
  申请人：Watterson D. Martin

  公开号：US20120245125A1

  公开（公告）日：2012-09-27

  The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for, research, drug screening, and therapeutic applications.

  本发明涉及新型化合物、组合物及其制备和使用的方法。特别是，本发明提供了吡嗪化合物和/或相关的杂环衍生物，包括这些化合物的组合物，以及制备和使用这些吡嗪化合物和/或相关的杂环衍生物和组合物的方法，用于调节细胞通路（例如信号转导通路），用于治疗或预防炎症性疾病（例如阿尔茨海默病），用于研究、药物筛选和治疗应用。
• COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS
  申请人：WATTERSON D. Martin

  公开号：US20120157410A1

  公开（公告）日：2012-06-21

  The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

  本发明涉及含有吡啶二氮化合物和胆碱酯酶抑制剂的组合物、共轭物和方法，用于调节细胞途径（例如，信号转导途径），用于治疗或预防炎症性疾病（例如，阿尔茨海默病），用于研究、药物筛选和治疗应用。
• Pyridazine compounds for the treatment of inflammatory diseases
  申请人：Northwestern University

  公开号：EP2592075A1

  公开（公告）日：2013-05-15

  The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. Compounds of Formula Ia or Ib or wherein R is a substituted amino group, R2 is an unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, R3, R4, R5, and R6 are hydrogen, and R7 is absent; or a pharmaceutically acceptable salt thereof.

  本发明涉及新型化合物、组合物及其制造和使用方法。特别是，本发明提供了哒嗪化合物和/或相关杂环衍生物、包含这些化合物的组合物，以及制造和使用哒嗪化合物和/或相关杂环衍生物及包含这些化合物的组合物的方法，用于调节细胞通路（如信号转导通路）、治疗或预防炎症性疾病（如阿尔茨海默氏症）、研究、药物筛选和治疗应用。 式 Ia 或 Ib 的化合物 或 其中 R 是取代的氨基，R2 是含有 1 至 4 个氮原子的不饱和 5 至 6 元杂环基团，R3、R4、R5 和 R6 是氢，R7 不存在；或其药学上可接受的盐。